Co-founder and VP of Development at eXoZymes, Dr. Paul Opgenorth, states: "The Large Language...

BioClick: Exponentially increasing the rate of data acquisition by coupling AI with enzyme...

eXoZymes Inc. (NASDAQ: EXOZ) (“eXoZymes”) - a pioneer of AI-engineered enzymes that can transform...

Our new Chief Commercial Officer, Damien Perriman, brings more than two decades of experience in...

Interviews with eXoZymes co-founders, Tyler Korman, PhD - and - Paul Opgenorth, PhD, sharing how...

An hour of eXoZymes’ employees and messages as displayed on the Nasdaq tower in New York City on...

Part of the coverage of eXoZymes’ closing bell ceremony on Feb 19, 2025 from CNBC. Credit: CNBC...

This Michael Heltzen's (CEO of eXoZymes) closing bell speech from February 19, 2025, when...

Captured on Feb 19, when the eXoZymes team rang the closing bell at Nasdaq in New York....

What is the difference between enzymes and exozymes? Listen to our CEO, Michael Heltzen, explain...